---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-027450"
form_type: "8-K"
ticker: "PRPO"
cik: "0001043961"
company_name: "Precipio, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:23:56.868236+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Precipio reports preliminary 2021 revenue of $8.9M, up 45% YoY; Q4 revenue $2.4M up 25%

## Summary
- Preliminary unaudited 2021 revenue $8.9M, up $2.8M (45%) from 2020.
- Q4-2021 revenue $2.4M, a 25% increase from $1.9M in Q4-2020.
- HemeScreen product Q4-2021 revenue $0.4M vs <$0.1M full-year 2020; annualized contracts now >$1.6M.
- 2022 outlook projects meaningful growth in pathology and HemeScreen, aiming to materially reduce cash burn.
- New panels (CLL, BCR-ABL) expected in 2022 to drive revenue per customer.

## SEC filing metadata
- accession: 0001104659-22-027450
- form_type: 8-K
- ticker: PRPO
- cik: 0001043961
- company_name: Precipio, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/0001104659-22-027450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1043961/000110465922027450/tm227800d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-027450
- JSON: https://secwatch.observer/filing/0001104659-22-027450.json
- Plain text: https://secwatch.observer/filing/0001104659-22-027450.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.